The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pan-tumor prognostic value of multiple immune protein expressions.
 
Tiphaine Lambert
No Relationships to Disclose
 
Loic Verlingue
Consulting or Advisory Role - Adaptherapy; Pierre Fabre
 
Léo Colmet-Daage
No Relationships to Disclose
 
Brice Rauby
No Relationships to Disclose
 
Nicolas Sanchez-Escobar Aladro
No Relationships to Disclose
 
Marie Kerisit
No Relationships to Disclose
 
Stephane Champiat
Research Funding - Abbvie (Inst); Agios (Inst); Amgen (Inst); arGEN-X BVBA (Inst); Arno Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Aventis Pharma (Inst); AVEO; Bayer (Inst); BBB Technologies (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); GamaMabs Pharma (Inst); Genentech (Inst); GlaxoSmithKline; H3 Biomedicine; Innate Pharma (Inst); Institut de Recherches Internationales Servier (Inst); Janssen-Cilag (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merrimack (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Nektar (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Octimet (Inst); Oncoethix (Inst); Onyx (Inst); Orion (Inst); Oryzon Genomics (Inst); Pfizer (Inst); Pharma Marathi (Inst); Pierre Fabre (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Xencor (Inst)
 
Muriel Wartelle
No Relationships to Disclose
 
Francois Lion
No Relationships to Disclose
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Biogen (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inivata (Inst); Ipsen (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Onxeo (Inst); Pfizer (Inst); PharmaMar (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); Tiziana Therapeutics (Inst)
 
ERIC ANGEVIN
Consulting or Advisory Role - Celgene; GlaxoSmithKline; MedImmune; Merck Sharp & Dohme
Research Funding - Abbvie; GlaxoSmithKline; MedImmune; Octimet; Pfizer; Sanofi
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Innate Pharma
 
Antoine Hollebecque
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Lilly; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Jean-Charles Soria
Employment - MedImmune
Honoraria - MedImmune; Merus; MSD Oncology; Pfizer; Roche; Symphogen
 
Jean-Yves Scoazec
No Relationships to Disclose
 
Christophe Massard
Consulting or Advisory Role - Amgen; Amgen; Astellas Oncology; Astellas Oncology; AstraZeneca; AstraZeneca; Bayer; Bayer; BeiGene; BeiGene; BMS Brazil; BMS Brazil; Celgene; Celgene; Debiopharm Group; Debiopharm Group (Inst); Genentech; Genentech; Ipsen; Ipsen; Janssen; Janssen; Lilly; Lilly; MedImmune; MedImmune; Novartis; Novartis; Pfizer; Pfizer; Roche; Roche; Sanofi; Sanofi
Research Funding - Abbvie (Inst); Abbvie (Inst); Agios (Inst); Agios (Inst); Amgen (Inst); Amgen (Inst); arGEN-X BVBA (Inst); arGEN-X BVBA (Inst); Arno Therapeutics (Inst); Arno Therapeutics (Inst); Astex Pharmaceuticals (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Aventis Pharma (Inst); Aventis Pharma (Inst); AVEO (Inst); AVEO (Inst); Bayer Health (Inst); Bayer Health (Inst); BBB Technologies (Inst); BBB Technologies (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Eisai (Inst); Eisai (Inst); Exelixis (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); FORMA Therapeutics (Inst); GamaMabs Pharma (Inst); GamaMabs Pharma (Inst); Genentech (Inst); Genentech (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); H3 Biomedicine (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Institut de Recherches Internationales Servier (Inst); Institut de Recherches Internationales Servier (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Lytix Biopharma (Inst); Lytix Biopharma (Inst); MedImmune (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck Sharp & Dome (Inst); Merck Sharp & Dome (Inst); Merrimack (Inst); Merrimack (Inst); Merus (Inst); Merus (Inst); Millennium (Inst); Millennium (Inst); Nanobiotix (Inst); Nanobiotix (Inst); Nektar (Inst); Nektar (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Octimet (Inst); Octimet (Inst); Oncoethix (Inst); Oncoethix (Inst); Onyx (Inst); Onyx (Inst); Orion (Inst); Orion (Inst); Oryzon Genomics (Inst); Oryzon Genomics (Inst); Pfizer (Inst); Pfizer (Inst); Pharma Marathi (Inst); Pharma Marathi (Inst); Pierre Fabre (Inst); Pierre Fabre (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tesaro (Inst); Xencor (Inst); Xencor (Inst)